Zhen Juanying, Liu Shuyun, Liu Lin, Zheng Xiaodan, Zhao Guoru, Liang Jianguo, Xu Aimin, Li Chao, Ren Lijie, Wu Jun, Cheung Bernard Man Yung
Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, China.
Department of Neurology, Peking University Shenzhen Hospital, Shenzhen, China.
Ann Med. 2025 Dec;57(1):2500689. doi: 10.1080/07853890.2025.2500689. Epub 2025 May 12.
Our research team previously found that fibroblast growth factor (FGF) 21, a circulating hormone, was significantly associated with atherosclerosis in human and animal models. The relationship between FGF21 and blood pressure (BP) is rarely studied in the Asian population. Therefore, we aimed to explore the relationship of FGF21 with BP in a Chinese population.
We analysed data on 1051 participants from the Shenzhen-Hong Kong United Network on Cardiovascular Disease (SHUN-CVD) study.
The medians of FGF21 level were 355.1 pg/mL (IQR 234.3-574.8 pg/mL) for hypertensive patients and 253.5 (IQR 136.9-403.3 pg/mL) for non-hypertensive participants. Ln-transformed FGF21 level was associated with both systolic and diastolic BP (systolic BP: = 4.45 [95% CI 3.41-5.49]; < .001; diastolic BP: = 2.72 [95% CI 2.03-3.42]; < .001). After adjusting for sex, age, body mass index, hypercholesterolaemia, diabetes, alcohol consumption, smoking and physical activity, the association remained significant (systolic BP: = 1.99 [95% CI 1.01-2.97]; < .001; diastolic BP: = 1.36 [95% CI 0.69-2.04]; < .001). Serum FGF21 level was associated with hypertension (quartile 4 vs. quartile 1, OR = 4.19 [95% CI 2.65-6.61]; for trend < .001).
This is the first study to elucidate the relationship of FGF21 with BP in the Asian population. FGF21 is significantly associated with BP. Besides its use as a biomarker, FGF21 may be a new drug target for hypertension treatment.
我们的研究团队之前发现，成纤维细胞生长因子（FGF）21作为一种循环激素，在人类和动物模型中与动脉粥样硬化显著相关。在亚洲人群中，FGF21与血压（BP）之间的关系鲜有研究。因此，我们旨在探讨中国人群中FGF21与血压的关系。
我们分析了来自深圳-香港心血管疾病联合网络研究（SHUN-CVD）的1051名参与者的数据。
高血压患者的FGF21水平中位数为355.1 pg/mL（四分位间距[IQR]为234.3 - 574.8 pg/mL），非高血压参与者为253.5（IQR为136.9 - 403.3 pg/mL）。经自然对数转换的FGF21水平与收缩压和舒张压均相关（收缩压：β = 4.45 [95%置信区间（CI）3.41 - 5.49]；P <.001；舒张压：β = 2.72 [95% CI 2.03 - 3.42]；P <.001）。在调整性别、年龄、体重指数、高胆固醇血症、糖尿病、饮酒、吸烟和体力活动后，这种关联仍然显著（收缩压：β = 1.99 [95% CI 1.01 - 2.97]；P <.001；舒张压：β = 1.36 [95% CI 0.69 - 2.04]；P <.001）。血清FGF21水平与高血压相关（四分位数4与四分位数1相比，比值比[OR] = 4.19 [95% CI 2.65 - 6.61]；趋势P <.001）。
这是第一项阐明亚洲人群中FGF21与血压关系的研究。FGF21与血压显著相关。除用作生物标志物外，FGF21可能是高血压治疗的新药物靶点。
